Abstract: This invention relates to a composition and a method for prediction of a response to Trastuzumab therapy in a breast cancer patient, and more specifically, a composition, a kit, a DNA chip, and a method for predicting a response to Trastuzumab therapy by using polynucleotides each comprising a nucleotide sequence represented by any of SEQ ID NOs: 1 to 9, 11 to 19, and 21 to 23 in the Sequence Listing or a nucleotide sequence derived therefrom by substitution of u with t, mutants thereof, derivatives thereof, or fragments thereof comprising at least 16 continuous nucleotides, or a polynucleotide comprising a complementary sequence thereof, and using an increase or decrease in Her2 protein expression level as an indicator.

Abstract: Improved methods of assessing status of a solid tumor cancer in a subject involving detection of tumor-associated mutations in the subject's blood.

Abstract: Methods and kits for characterizing a subject having a steroid-dependent disease such as prostate cancer are described. A method of treating a steroid-dependent disease in a subject by obtaining a biological sample from the subject, determining if the HSD3B1(1245C) gene or 3?HSD1(367T) protein is expressed in the biological sample, and providing treatment other than or in addition to steroid ablation to the subject if the HSD3B1(1245C) gene or 3?HSD1(367T) protein is expressed is also described.

Abstract: In one aspect, the invention is directed to a method of detecting Cowden syndrome (CS) or CS-like syndrome in an individual comprising detecting the presence of a mutated succinate dehydrogenase B (SDHB), mutated succinate dehydrogenase D (SDHD) or combination thereof in the individual, wherein detection of a mutated SDHB, SDHD or a combination thereof indicates that the individual is positive for CS or CS-like syndrome. In another aspect, the invention is directed to a method of determining whether an individual is at risk for developing Cowden syndrome (CS) or CS-like syndrome comprising detecting the presence of a mutated succinate dehydrogenase B (SDHB), mutated succinate dehydrogenase D (SDHD) or combination thereof in the individual, wherein detection of a mutated SDHB, SDHD or a combination thereof indicates that the individual is at risk for developing for CS or CS-like syndrome.

Abstract: The invention relates to methods for predicting the onset of extrapyramidal symptoms (EPS) induced by an antipsychotic-based treatment as well as methods for providing personalized medicine to patients based on the sequence of several SNPs associated with the onset of EPS. The invention relates as well to kits for carrying out the diagnostic and predictive medicine methods.

Abstract: A nucleic acid molecule utilizable for Salmonella detection is provided. The nucleic acid molecule which binds to Salmonella includes any of the following polynucleotides (a) to (d): (a) a polynucleotide composed of any of base sequences of SEQ ID NOs: 1 to 17; (b) a polynucleotide composed of a base sequence obtained by deletion, substitution, insertion, and/or addition of one or more bases in any of the base sequences in the polynucleotide (a) and is bound to Salmonella; (c) a polynucleotide composed of a base sequence having an identity of 80% or more to any of the base sequences in the polynucleotide (a) and is bound to Salmonella; and (d) a polynucleotide composed of a base sequence complementary to a polynucleotide which hybridizes to the polynucleotide (a) composed of any of the base sequences under stringent conditions and is bound to Salmonella.

Abstract: The present methods are exemplified by a process in which maternal blood containing fetal DNA is diluted to a nominal value of approximately 0.5 genome equivalent of DNA per reaction sample. Digital PCR is then be used to detect aneuploidy, such as the trisomy that causes Down Syndrome. Since aneuploidies do not present a mutational change in sequence, and are merely a change in the number of chromosomes, it has not been possible to detect them in a fetus without resorting to invasive techniques such as amniocentesis or chorionic villi sampling. Digital amplification allows the detection of aneuploidy using massively parallel amplification and detection methods, examining, e.g., 10,000 genome equivalents.

Abstract: The oligonucleotide of sequence SEQ ID No.1: 5?-CTAGAGATCCCTCAGA-3?, and the complementary sequence thereof of sequence SEQ ID No.2: 5?-TCTGAGGGATCTCTAG-3? useful as probes to detect and quantify all HIV-1 circulating forms and their precursors SIVcpz/SIVgor.

Abstract: A method for diagnosing and/or evaluating dementia severity in a subject suspected of having or having dementia is provided the method comprising: a) obtaining a test cell sample from the subject, b) assaying the test cell sample to determine a telomere organization signature of the test sample, the telomere organization signature comprising one or more parameters selected from: i) telomere aggregates; ii) telomere number; iii) telomere length and telomere number; iv) telomere aggregates, telomere length and telomere numbers; c) comparing the test cell sample telomere organization signature to a control or one or more predetermined reference signatures; and d) diagnosing whether the subject has dementia and/or the dementia severity according to the test sample telomere organization signature.

Abstract: The present invention provides a method for evaluating (predicting, etc.) an individual difference (the tendency of every individual) in terms of drug sensitivity and disease vulnerability, comprising using a gene polymorphism of a cyclic AMP responsive element binding protein gene or the like. The method for evaluating drug sensitivity and the method for evaluating disease vulnerability according to the present invention comprise associating a gene polymorphism of a cyclic AMP responsive element binding protein gene or a haplotype constituted by the gene polymorphism with the drug sensitivity and disease vulnerability of an individual.

Abstract: Methods and materials for detection of aneuploidy and other chromosomal abnormalities using fetal tissue are disclosed. Results can be obtained rapidly, without cell culture. The method uses digital PCR for amplification and detection of single target sequences, allowing an accurate count of a specific chromosome or chromosomal region. Specific polynucleic acid primers and probes are disclosed for chromosomes 1, 13, 18, 21, X and Y. These polynucleic acid sequences are chosen to be essentially invariant between individuals, so the test is not dependent on sequence differences between fetus and mother.

Abstract: The invention provides methods and compositions for early diagnosis and treatment of a disease associated with a specific antibody by employing the detection of a cross-idiotypic epitope on the specific antibody to detect the cells that produce the antibody before the development of clinical symptoms of the disease.

Abstract: The present application relates to an ex vivo or in vitro method to determine the presence or absence of a mutation or a variation in the NF-E2 gene in a sample from a patient suffering from a myeloid neoplasm or solid tumor whereby said method comprises: a) obtaining a nucleic acid sample from the patient, b) detecting the presence or absence of a mutation in the nucleic acid sample comprising the NF-E2 gene or a fragment thereof, characterized in that the presence of the mutation is an indication of a myeloid neoplasm or solid tumor, whereby the mutation is determined by comparing the nucleic acid sequence obtained from the sample with SEQ ID NO:1 or the complement thereof.

Abstract: The invention relates to the fields of therapeutics and identifying candidates for therapy, in particular to a method of identifying candidates for trastuzumab (Herceptin®) therapy in a patient presenting with breast cancer based on the presence or absence of specific genetic markers in a tumor sample from said patient.

Abstract: This document provides methods and materials involved in detecting translocations of TBL1XR1 and TP63 nucleic acid. For example, methods and materials for detecting TBL1XR1 and TP63 gene rearrangements (e.g., translocations) associated with cancer (e.g., T-cell lymphomas) as well as methods and materials for detecting cancers (e.g., T-cell lymphomas) with a dominant negative TP63 phenotype are provided.

Abstract: A method of identifying a subject with increased risk of colorectal cancer includes obtaining a biological sample from the subject, measuring the level of Fusobacterium nucleatum in the biological sample, and comparing the measured level to a control level, wherein an increased measured level compared to the control level is indicative of increased risk of colorectal cancer in the subject.

Abstract: Oligomers useful for determining the presence of Trichomonas vaginalis in a test sample.

Abstract: Provided in the present invention are a method using in vitro measurement of the content of methylation or demethylation of GFRa1 CpG islands to estimate a risk of tumorigenesis and of tumor metastasis, or postoperative life expectancy, and a nucleotide sequence used.

Abstract: Nucleic acids and proteins having a mutant C-RAF sequence, and methods of identifying patients having cancer who are likely to benefit from a combination therapy and methods of treatment are provided.

Abstract: The present invention is related to the novel discovery of a number of genes that were identified as systemic markers of pulmonary inflammation. This discovery allows for development of a novel tool for reliable, rapid and efficient assessment of therapeutic responses and enables design of novel therapies targeted against diseases associated with pulmonary inflammation. In one embodiment, the present invention allows quantification of therapeutic response in patients who have a disease associated with pulmonary inflammation. In preferred embodiments, the genes are CD64, ADAM9, CD36, IL32, HPSE, PLXND1, HCA112, CSPG2, TLR2, and CD163.